Cymabay Therapeutics Inc. (NASDAQ:CBAY): Jim Tananbaum’s Foresite Capital Fund III, L.P. filed an amended 13D.
You can check out Foresite Capital’s latest holdings and filings here.
Please follow Foresite Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Foresite Capital or update its stock holdings.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Foresite Capital Fund III||600,000||600,000||600,000||1.4%|
|Foresite Capital Management III||600,000||600,000||600,000||1.4%|
|Foresite Capital Fund IV||2,091,792||2,091,792||2,091,792||4.7%|
|Foresite Capital Management IV||2,091,792||2,091,792||2,091,792||4.7%|
|James Tananbaum ( Tananbaum )||2,691,792||2,691,792||2,691,792||6.2%|
Page 1 of 11 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No. ___________)*
Common Stock, par value $0.0001
November 1, 2017
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following pages)
Page 1 of 11
Exhibit Index on Page 10